Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ampligen + durvalumab
- Development stage
- Unknown
- Lead developer
- AIM ImmunoTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ampligen (rintatolimod) plus durvalumab is an investigational combination therapy being studied primarily for the treatment of late-stage pancreatic ductal adenocarcinoma. Ampligen is a double-stranded RNA (dsRNA) and highly selective toll-like receptor 3 (TLR3) agonist immunomodulator, developed by AIM ImmunoTech, that aims to reprogram the immune system and enhance cellular immune responses. Durvalumab, marketed as Imfinzi by AstraZeneca, is a monoclonal antibody that acts as an immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1), thereby enabling the immune system to recognize and attack cancer cells. The combination seeks to leverage both innate and adaptive immunity for improved anti-tumor efficacy. Clinical trials are ongoing in metastatic pancreatic cancer patients who have progressed after standard chemotherapy[1][4][6][7].
- Brand names
- Imfinzi
- Other names
- Ampligen + durvalumabrintatolimod + durvalumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on Ampligen + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ampligen + durvalumab.